Key result
Patients with cardiac amyloidosis had reduced flicker-induced arterial dilatation compared to healthy controls.
Why the study?
The role of microvascular dysfunction in cardiac amyloidosis pathophysiology remains elusive, despite vascular function being associated with cardiovascular risk, heart failure severity, and therapeutic potential.
Does cardiac amyloidosis impair retinal microvascular function compared to healthy controls?
Cross-Sectional (n=103)
Does cardiac amyloidosis impair retinal microvascular function compared to healthy controls?
Retinal microvascular function is significantly impaired in patients with cardiac amyloidosis and correlates with cardiac and renal biomarkers of disease severity, suggesting a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Impaired retinal microvascular function may occur in cardiac amyloidosis; hypothesis-generating for biomarker or therapeutic target potential.
AIMS: Cardiac involvement in systemic amyloidosis is a marker of particularly poor prognosis. Cardiac amyloidosis (CA) is characterized by extracellular amyloid deposits inducing heart failure and symptoms of cardiac microvascular disease. While amyloid deposition is most common in the myocardium but also seen in pericardium and endocardium, atria, and vasculature, the role of (micro-)vascular dysfunction in CA pathophysiology remains still elusive. Because vascular function is associated with cardiovascular risk and severity of heart failure and represents a potential therapeutic target in CA, the present study investigated retinal vascular function, flow-mediated dilatation (FMD), and pulse-wave analysis and velocity (PWA/PWV) in patients with CA. METHODS AND RESULTS: Flicker-induced arterial dilatation (FIDa) was measured using dynamic retinal vessel analysis additionally to FMD and PWA/PWV. Thirty-three patients with CA [age 67 years [interquartile range, IQR, 62, 74], 14 with amyloid light-chain (AL) and 19 with transthyretin (ATTR) amyloidosis] were prospectively included in this cross-sectional, observational study and 70 healthy individuals (age 53 years [IQR 39, 67]) served as control. Potential confounders were balanced using entropy balancing propensity score analysis [inverse probability weighting (IPW)]. FIDa was reduced in CA patients (1.52 ± 1.73% vs. 3.09 ± 1.96%, P < 0.001, after IPW). While PWV was increased (8.74 ± 2.34 m/s vs. 7.49 ± 1.65 m/s, P = 0.018, after IPW), no difference in FMD was observed. FIDa was significantly associated with prognostic biomarkers of CA [estimated glomerular filtration rate (r = 0.33; P < 0.001), log-scaled troponin T (r = -0.49; P < 0.001), and N-terminal pro-B-type natriuretic peptide (r = -0.51; P < 0.001)]. CONCLUSIONS: Retinal vascular function is impaired, associated with cardiac and renal biomarkers of CA severity, and may represent a potential therapeutic target in patients with amyloidosis.
No takes yet. Share an insight, caveat, or question.
Zampiccoli et al. (2022) conducted a cross-sectional in Cardiac amyloidosis (n=103). Cardiac amyloidosis vs. Healthy individuals was evaluated on Flicker-induced arterial dilatation (FIDa) (p=<0.001). Patients with cardiac amyloidosis had reduced flicker-induced arterial dilatation compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: